Core Points - In the first half of 2025, the company achieved operating revenue of 2.65 billion yuan, a year-on-year decrease of 33.15% [1][2] - The net profit attributable to shareholders increased to 1.93 billion yuan, representing a year-on-year growth of 193.08% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 596 million yuan, a decrease of 5.93% year-on-year [1][2] Financial Data Summary - Operating revenue for the first half of the year was 2,650,519,061.55 yuan, down from 3,964,740,785.30 yuan in the same period last year [2] - Total profit for the period was 2,267,022,653.76 yuan, compared to 747,648,928.95 yuan in the previous year [2] - The net profit attributable to shareholders was 1,927,622,964.41 yuan, up from 657,719,254.85 yuan year-on-year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 596,244,037.42 yuan, down from 633,831,191.83 yuan [2] - The net cash flow from operating activities was 487,741,377.69 yuan, compared to 555,214,560.54 yuan in the previous year [2] - As of the end of the reporting period, the net assets attributable to shareholders were 8,784,931,304.31 yuan, up from 7,843,592,378.84 yuan at the end of the previous year [2] - Total assets amounted to 12,853,461,645.69 yuan, compared to 10,768,625,044.29 yuan at the end of the previous year [2] Business Operations - The decline in mid-year revenue is attributed to the company no longer recognizing income from its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd., which was transferred to Tianyao Taiping Pharmaceutical Co., Ltd. at the end of 2024 [1][2] - The increase in net profit attributable to shareholders is primarily due to the transfer of 12% equity in Tianjin Shike Pharmaceutical Co., Ltd., resulting in a post-tax net gain of 1.308 billion yuan [3] - The decrease in net profit after deducting non-recurring gains and losses is linked to the sale of 25% equity in Tianjin Shike, which resulted in the absence of investment income from this associate company in the current period [3] Leadership and Compensation - The chairman of the company is Wang Lei, a female executive aged 54, who has held various positions within the company since 2022 [3] - Wang Lei's compensation was 2.625 million yuan in 2023 and decreased to 1.934 million yuan in 2024 [4]
达仁堂上半年净利大增193%,54岁女董事长王磊去年底上任